• 1
    MacArthur JM, Bishop JR, Stanford KI, Wang L, Bensadoun A, Witztum JL, et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest 2007; 117: 153164.
  • 2
    Mahley RW, Weisgraber KH, Innerarity TL. Interaction of plasma lipoproteins containing apolipoproteins B and E with heparin and cell surface receptors. Biochim Biophys Acta 1979; 575: 8191.
  • 3
    Ji ZS, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem 1993; 268: 1016010167.
  • 4
    Ji ZS, Sanan DA, Mahley RW. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res 1995; 36: 583592.
  • 5
    Otsu K, Kato S, Ohtake K, Akamatsu N. Alteration of rat liver proteoglycans during regeneration. Arch Biochem Biophys 1992; 294: 544549.
  • 6
    Roskams T, Rosenbaum J, De Vos R, David G, Desmet V. Heparan sulfate proteoglycan expression in chronic cholestatic human liver diseases. HEPATOLOGY 1996; 24: 524523.
  • 7
    Murata K, Ochiai Y, Akashio K. Polydispersity of acidic glycosaminoglycan components in human liver and the changes at different stages in liver cirrhosis. Gastroenterology 1985; 89: 12481257.
  • 8
    Kovalszky I, Pogany G, Molnar G, Jeney A, Lapis K, Karacsonyi S, et al. Altered glycosaminoglycan composition in reactive and neoplastic human liver. Biochem Biophys Res Commun 1990; 167: 883890.
  • 9
    Ji ZS, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem 1994; 269: 1342113428.
  • 10
    Forsberg E, Kjellen L. Heparan sulfate: lessons from knockout mice. J Clin Invest 2001; 108: 175180.
  • 11
    Fuki IV, Kuhn KM, Lomazov IR, Rothman VL, Tuszynski GP, Iozzo RV, et al. The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest 1997; 100: 16111622.
  • 12
    Wilsie LC, Gonzales AM, Orlando RA. Syndecan-1 mediates internalization of apoE-VLDL through a low density lipoprotein receptor-related protein (LRP)-independent, non-clathrin-mediated pathway. Lipids Health Dis 2006; 5: 23.
  • 13
    Zeng BJ, Mortimer BC, Martins IJ, Seydel U, Redgrave TG. Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J Lipid Res 1998; 39: 845860.
  • 14
    Cortés V AL, Donoso K, Valencia I, Quiñones V, Zanlungo S, Brandan E, et al. Adenovirus-mediated hepatic syndecan-1 overexpression induces hepatocyte proliferation and hyperlipidemia in mice. Liver Int; in press.
  • 15
    Kjellen L, Bielefeld D, Hook M. Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 1983; 32: 337342.
  • 16
    Ebara T, Conde K, Kako Y, Liu Y, Xu Y, Ramakrishnan R, et al. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 2000; 105: 18071818.
  • 17
    Anisfeld AM, Kast-Woelbern HR, Meyer ME, Jones SA, Zhang Y, Williams KJ, et al. Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. J Biol Chem 2003; 278: 2042020428.